U.S. stem cell policy deters investors

WASHINGTON, Nov. 2 (UPI) -- Venture capitalists think the Bush administration's restrictions on embryonic stem cell research are discouraging investors from backing companies working on these cells, which could delay potentially life-saving medical therapies from reaching the public. The policy also could lead to a exodus of U.S. scientists and enable other countries to reap vast financial rewards expected to come from these medical therapies.